SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Goldman Sachs upgrade to Buy, citing sovereign-AI demand and growth in customized software, is reinforcing Palantirs AI growth story as the stock reaches fresh highs. Bulls are celebrating the breakout and speculating about a short squeeze, while skeptics warn that the valuation is stretched and the rally could pull back.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs sharp rally is drawing attention to Starknets privacy and Bitcoin DeFi push, including strkBTC and STRK20, alongside its post-quantum security narrative. Traders are largely bullish on the technology and momentum, while some remain wary of token unlocks and selling pressure.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is drawing attention for choppy, range-bound trading, with repeated failures to clear the psychologically important 10-cent level fueling frustration. Bulls are calling the pullbacks accumulation opportunities and anticipating a breakout alongside a broader crypto rally, while bears see the stalled price action as a sign of further weakness.

Air Canada engages in the provision of airline transportation services. Its services cover full-service airline, scheduled passenger and cargo services, serving more than two hundred airports on six continents. It operates through the following geographical segments: Canada, U.S. Transborder, Atlantic, Pacific, and Other. The company was founded on April 11, 1936 and is headquartered in Saint-Laurent, Canada.

Air Canada Inc. - Ordinary Shares (Voting and Variable Voting)

Air Canada Inc.

Air Canadas sharp selloff and underperformance versus U.S. airline peers are driving discussion, with traders citing oil and fuel-cost uncertainty and speculating about shorting or selling pressure after the share bid. Bears see further downside, while bulls point to buybacks and Aeroplans value as reasons for optimism.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

T-Mobile shares sold off sharply after SpaceX agreed to acquire low-band spectrum for Starlink Mobile, raising fears that it could eventually compete with established wireless carriers. Traders are divided between seeing a lasting competitive threat and viewing the reaction as excessive, arguing that building a capable terrestrial network would take substantial time and investment.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

A report of a planned NIH-backed push to accelerate personalized cancer vaccines has lifted vaccine stocks, including BioNTech. Traders are discussing the sector rally and BioNTechs oncology pipeline, while some question why BNTX is lagging Moderna.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is drawing attention after its and Modernas personalized cancer vaccine with Keytruda met key endpoints in a Phase 3 melanoma trial, renewing interest in the companies oncology pipeline. Traders see potential beyond melanoma and a boost to Mercks growth outlook, while others caution that full results, overall-survival data, and broader commercial potential remain uncertain.

Fortinet, Inc. provides cybersecurity solutions to a variety of businesses, such as enterprises, communication service providers, government organizations, and small to medium-sized businesses. Its product portfolio includes network security, secure access service edge, enterprise networking, security operations, application security, and operational technology. The company was founded by Ken Xie and Michael Xie in November 2000 and is headquartered in Sunnyvale, CA.

Fortinet Inc

Fortinets push to fresh highs is drawing attention amid strength across cybersecurity stocks and optimism that AI-related security risks will support demand. Traders are split between momentum continuing and concern that stretched valuations and light trading volume leave the rally vulnerable to a pullback.

Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce. Its platform consists of three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company was founded by Max R. Levchin in 2012 and is headquartered in San Francisco, CA.

Affirm Holdings Inc - Ordinary Shares - Class A

Affirm Holdings Inc

Affirms strong quarterly results and upbeat outlook, followed by analyst upgrades, are driving attention. Traders remain divided: bulls see growth and a rebound opportunity, while bears point to the sharp post-earnings reversal and risks from valuation, interest rates, and consumer credit.

Voyager Technologies, Inc. engages in the defense technology and space solutions. It operates through the following segments: Defense and Space Technologies, and Starlab Space Stations. The Defense and Space Technologies segment consists of innovative mission-critical solutions to protect dynamic and contested domains. The Starlab Space Stations segment consists of a commercial space station. The company was founded by Dylan Taylor and Matthew Kuta on August 15, 2019 and is headquartered in Denver, CO.

Voyager Technologies Inc. - Ordinary Shares - Class A

Voyagers sharp selloff and persistent underperformance versus other space stocks dominate the discussion, with traders blaming financing and potential dilution concerns around a convertible-note offering. Bearish frustration over management and cash use contrasts with some traders viewing the decline as a buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Year-ender 2025 view on Indian pharma achievements

2025 felt like a quiet reset for Indian pharma. Exports and policy support remained important, but the more meaningful shift was in what people focused on inside companies and hospitals, said Saransh Chaudhary, president, global critical care, Venus Remedies and chief executive, Venus Medicine Research Center in a personal view on the Indian pharmaceutical sector.

Bad drugs or no drugs: Cancer patients face scary reality tied to foreign supply chain

… shelves of pharmacies rooted in the production of drugs in India … U.S., supplied by Intas Pharmaceuticals , failed one out of … us inside the oncology pharmacy where the drugs that save his … broken system. -- Intas Pharmaceuticals and Venus Remedies did not …

Ixigo And Venus Remedies Show Long-term Upside Potential: SEBI RA Gunjan Kumar 

Equity

The analyst eyes breakout opportunities in these two stocks, driven by their technical strength and growing institutional interest.

Big pharma pivoting to more lucrative obesity segment, Indian drugmakers eye insulin market

… or Sanofi , while one brand, Huminsulin by US-based pharma giant Eli Lilly , … care) of research-driven pharma company Venus Remedies. Innovative … case of small molecule drugs —have now hit the … “The entry of multiple pharmaceutical companies into this space …

Medivirs CEO to BioStock: I am proud to see our research contribute to a global solution

Antibiotic resistance is a growing global crisis, increasing the urgency for effective treatments. While Medivir now focuses on cancer therapies, it has a legacy in antimicrobial research. This was highlighted by Infex Therapeutics licensing agreement with Venus Remedies Ltd for the development of MET-X in India a compound developed from a research program that Medivir outlicensed in 2017. We reached out to Medivirs CEO Jens Lindberg for a comment. Read the interview with Jens Lindberg at biostock.se: https://www.biostock.se/en/2025/03/medivirs-ceo-i-am-proud-to-see-our-research-

India, EU to renew FTA negotiations

India and the European Union will this week take stock of their negotiations for an ambitious free trade deal and broadly firm up a new strategic agenda. Venus Remedies inks pact with UK firm New Delhi: Venus Remedies said it has joined hands with UK-based Infex Therapeutics for the development of MET-X, an inhibitor, to […]

Infex partners with Venus Remedies to develop MET-X in India

https://www.investing.com/news/company-news/infex-partners-with-venus-remedies-to-develop-metx-in-india-93CH-3888284

Venus Remedies Ltd. engages in the manufacture and trade of pharmaceutical products. Its products include analgesic, analgesic and antipyretic, anti diabetic, antibiotic, cardiac, disinfectant and antiseptic, gastro therapy, hand sanitizer, hormone, iron supplement, neurology, oncology, pain management, respiratory, skin care, stress reliever, urology, vitamins/minerals/nutrients, and wound management. The company was founded by Pawan Chaudhary on September 15, 1989 and is headquartered in Panchkula, India.

Current Price	1,624.80
Prev Close	1,681.00
Open	1,636.60
Dividend Yield	1.21%
50-Day Moving Average	1,660.71
Beta	0.02
Avg. Volume	27,482.38
PE Ratio	18.53

52-Week High	2,044.30
52-Week Low	432.10
Market Capitalization	22.4B
EPS (Annual)	76.90
Price to Book	3.24
Revenue Per Employee	5.02M

Feed

News

Sentiment

Fundamentals

Info

VENUSREM.NSE Fundamentals